Targeting NRF2 for the Treatment of Friedreich’s Ataxia: A Comparison among Drugs

• Main Authors: Sara Petrillo, Jessica D’Amico, Piergiorgio La Rosa, Enrico Silvio Bertini, Fiorella Piemonte
• Format: Article
• Language: English
• Published: MDPI AG 2019-10-01
• Series: International Journal of Molecular Sciences
• Subjects: friedreich’s ataxia; nrf2; redox active drugs; neurodegenerative disease; frataxin
• Online Access: https://www.mdpi.com/1422-0067/20/20/5211

NRF2 (Nuclear factor Erythroid 2-related Factor 2) signaling is impaired in Friedreich&#8217;s Ataxia (FRDA), an autosomal recessive disease characterized by progressive nervous system damage and degeneration of nerve fibers in the spinal cord and peripheral nerves. The loss of frataxin in patients results in iron sulfur cluster deficiency and iron accumulation in the mitochondria, making FRDA a fatal and debilitating condition. There are no currently approved therapies for the treatment of FRDA and molecules able to activate NRF2 have the potential to induce clinical benefits in patients. In this study, we compared the efficacy of six redox-active drugs, some already adopted in clinical trials, targeting NRF2 activation and frataxin expression in fibroblasts obtained from skin biopsies of FRDA patients. All of these drugs consistently increased NRF2 expression, but differential profiles of NRF2 downstream genes were activated. The Sulforaphane and <i>N</i>-acetylcysteine were particularly effective on genes involved in preventing inflammation and maintaining glutathione homeostasis, the dimethyl fumarate, omaxevolone, and EPI-743 in counteracting toxic products accumulation, the idebenone in mitochondrial protection. This study may contribute to develop synergic therapies, based on a combination of treatment molecules.